A year ago, the rivalry between Eli Lilly and Novo was the fiercest in the industry. Now, it looks increasingly one-sided. The best evidence might be investors' reactions to each company's third-quarter results. Both stocks ...

This is a summary of the story. Read the full article at Endpoints News (Biopharma) ↗